Loading...
Docoh

Vir Biotechnology (VIR)

News

From Benzinga Pro
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
12 May 22
Analyst Color, Biotech, News, Health Care, Price Target, Reiteration, Analyst Ratings, Movers, Trading Ideas, General
10 Biggest Price Target Changes For Thursday
12 May 22
Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Wells Fargo cut the price target on Ford Motor Company (NYSE: F) from $24 to $12. Ford shares fell 2.8% to $12.47 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Lowers Price Target to $125
12 May 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Patrick Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $200 to $125.
5 Value Stocks To Watch In The Healthcare Sector
9 May 22
News
What Defines a Value Stock?
Where Vir Biotechnology Stands With Analysts
6 May 22
Analyst Ratings
Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:
Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $35
6 May 22
News, Price Target, Analyst Ratings
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $45 to $35.
Vir Biotechnology Q1 EPS $3.85 Beats $3.78 Estimate, Sales $1.23B Beat $836.97M Estimate
5 May 22
Earnings, News
Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $3.85 per share which beat the analyst consensus estimate of $3.78 by 1.85 percent. This is a 391.67 percent increase over losses of $(1.32) per share from
Earnings Scheduled For May 5, 2022
5 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Outlook For Vir Biotechnology
4 May 22
Earnings
Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
2 May 22
Analyst Color, Biotech, News, Health Care, Analyst Ratings, Movers, Trading Ideas, General
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Vir Biotechnology Announces Data To Be Discussed During Today's Hepatitis Portfolio R&D Day
27 Apr 22
Biotech, News, Events, General
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00
5 Value Stocks In The Healthcare Sector
25 Apr 22
News
What are Value Stocks?
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here
6 Apr 22
Biotech, News, Health Care, FDA, General
51 Biggest Movers From Yesterday
31 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Forge Global Holdings, Inc. (NYSE: FRGE) jumped 73.9% to close at $37.64.
Mid-Afternoon Market Update: Dow Drops 100 Points; Adagio Therapeutics Shares Spike Higher
30 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping 100 points on Wednesday.
12 Health Care Stocks Moving In Wednesday's Intraday Session
30 Mar 22
Intraday Update, Markets, Movers
Mid-Day Market Update: Crude Oil Surges 3%; Revelation Biosciences Shares Plunge
30 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks traded lower midway through trading following the release of GDP data.
35 Stocks Moving In Wednesday's Mid-Day Session
30 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales guidance above analyst estimates.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
30 Mar 22
Movers
Gainers Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million.

Press releases

From Benzinga Pro
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
5 May 22
Earnings, Press Releases
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – –
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
27 Apr 22
Health Care, Press Releases
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
23 Apr 22
Press Releases
NEW YORK, April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vir Biotechnology, Inc. - VIR
21 Apr 22
Press Releases
New York, New York--(Newsfile Corp. - April 21, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
19 Apr 22
News, Legal, Press Releases
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to contact Robert
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
17 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 17, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc.("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
15 Apr 22
News, Legal, Press Releases
NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to contact Robert
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
13 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 13, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc.("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
13 Apr 22
News, Press Releases
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on Wednesday,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
11 Apr 22
Press Releases
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
9 Apr 22
Press Releases
New York, New York--(Newsfile Corp. - April 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
6 Apr 22
Press Releases
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge,
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Vir Biotechnology, Inc. (VIR) Investigation
5 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 5, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vir Biotechnology, Inc. ("Vir" or the "Company")
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Vir Biotechnology, Inc. – VIR
5 Apr 22
News, Legal, Press Releases
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ:VIR). Such investors are advised to contact Robert
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
4 Apr 22
Biotech, News, Press Releases, General
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday,
Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600
29 Mar 22
Mutual Funds, Markets, Press Releases
NEW YORK, March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE:CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
25 Mar 22
Health Care, Press Releases
SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the US Food and Drug Administration has amended the Emergency Use
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
2 Mar 22
News, Health Care, Press Releases
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual Cowen Healthcare
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
24 Feb 22
Earnings, Press Releases
– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial